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Executive summary 
Hepatitis C (HCV) is a blood borne virus that affects the liver and is predominately transmitted 
by contact with infected blood. In the UK, those at highest risk of contracting HCV are people 
who inject drugs (PWID), with national data demonstrating PWID account for over 90% of all 
HCV infections.  
 
Since 2014, direct-acting, all oral antiviral treatments have revolutionized the treatment of HCV 
as well as mitigating complications such as liver failure, liver cancer and the need for liver 
transplantation. Direct-acting antivirals (DAAs) are effective in curing the infection in more than 
90% of those infected with HCV of all genotypes, thus making the HCV elimination targets of the 
World Health Organisation (WHO) by 2030 and NHS England by 2025 achievable. 
 
Despite this, diagnosis and treatment rates in HCV positive people who are actively injecting 
remain low.  This vulnerable group faces many barriers to access existing services and need 
more accessible testing and treatment pathways given their high risks of HCV transmission and 
acquisition. The LJWG’s phase 1 pharmacy pilot offered HCV antibody testing to PWIDs 
accessing needle and syringe programmes (NSPs) at specific community pharmacies and 
provided pathways to secondary care for treatment.  
 
The LJWG’s pharmacy testing pilot, phase 2, builds on learning from phase 1 in order to increase 
testing and treatment for those most at risk of HCV acquisition and transmission. Phase 2 
provides point of care capillary blood testing for HCV RNA to PWIDs accessing NSPs from 
community pharmacies in London, whereas phase 1 tests provided on-the-spot HCV antibody 
testing. This change enables those with chronic HCV infection to be identified directly in the 
pharmacies. Both pilots aimed to ensure transition to treatment with pathways from NSP 
community pharmacies to tertiary treatment centres.  
 
Six pharmacies providing NSPs across London took part in the phase 2 pilot between April 2018 
and March 2019. Key findings were: 
• Of the 308 patients offered HCV testing across all sites, 57% accepted (n=176). 
• 38% (n = 66) tested positive for HCV, of whom 21% completed treatment (n=14). 
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• 29% (n=51) of those tested did not know that interferon-free treatment was 
available. 
• 78% (n=137) of those tested would prefer to receive HCV treatment in their 
community pharmacy, followed by 9% (n=16) reporting they would prefer to 
receive treatment from a GP practice. 
• Over three-quarters (78%) of people reported having previously been tested for 
HCV, and 41% said they had been tested within the last year. 
• 75% (n=132) of service users said they would recommend the pharmacy testing 
service to a friend. 
 
Following on from the success of the phase 1 pilot conducted in 2017-18, this report confirms 
the feasibility and value of offering point of care HCV diagnosis to PWIDs attending community 
pharmacies for needle exchange services. This report provides valuable insights for future HCV 
testing programmes in pharmacies and recommends a broader roll-out.  
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Background 
Hepatitis C is a blood borne virus that causes chronic liver disease. It is estimated that around 
113,000 people live with chronic HCV infection in England. People who inject drugs carry the 
greatest burden of infection, with around half of all PWIDs in England and Wales estimated to 
have been infected with HCV (1).  
 
The advent of direct-acting antivirals has revolutionised treatment of HCV, achieving virological  
cure or sustained virological response (SVR) in over 90% of patients. In the last few years, NHS 
England has expanded access to DAA treatment across the country, with patients being 
prioritised through Operational Delivery Networks (ODNs). To achieve elimination of HCV as a 
major public health threat by 2030, it is critical that treatment uptake is maximised in actively 
injecting PWIDs, the group most affected by this infection with the highest acquisition and 
transmission rates (1; 2).  
 
Previous studies have demonstrated that the delivery of HCV testing through pharmacies is an 
effective method of engaging with this cohort (3; 4; 5). A recent phase 1 pilot by the LJWG 
involving point of care testing using oral fluid test (OFT) for HCV antibody had demonstrable 
success in increasing testing uptake by PWIDs accessing needle and syringe programmes 
(NSPs) through community pharmacies in London (6). However, the phase 1 pilot had 
considerable loss to follow-up after pharmacy testing, as further investigation of RNA status 
through secondary care was required to confirm the diagnosis before treatment could be initiated 
in secondary care (6).  
 
Drawing upon learning from the phase 1 pilot, a phase 2 pilot was designed to evaluate chronic 
HCV diagnosis in this population using capilliary blood testing for HCV RNA instead of OFT used 
in phase 1. This was the first time worldwide that capilliary blood testing for HCV RNA was 
employed in a non-clinical setting. Enhanced peer support was also implemented to determine 
whether engagement with treatment services could be increased, and drop-out rates reduced. 
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Aims 
The aim of the phase 2 pilot was to reduce the impact of hepatitis C in actively injecting PWIDs, 
by facilitating access to immediate chronic HCV diagnosis in NSP community pharmacies using 
point of care testing HCV RNA capillary blood test and ensuring enhanced support for transition 
into treatment for this vulnerable population.  
 
The objectives of the analysis in this report are to: 
• Ascertain the prevalence of hepatitis C among the tested pilot cohort. 
• Determine uptake and loss to follow-up at each point in the care cascade.  
• Explore whether the service delivery model was acceptable to service users and 
pharmacy staff. 
• Identify barriers and facilitators to engagement with services. 
• Compare uptake and engagement with the phase 1 pilot to determine which 
elements of the service models are most effective at improving uptake.  
 
Methods 
The testing model in phase 2 was similar to phase 1, with the major difference being the use of 
Cepheid capillary blood test for HCV RNA detection. This was the first study worldwide to use 
the Cephied test in a non-clinical environment. Further details of the methodology can be found 
in the phase 1 report (6).  
 
Pharmacies were invited to take part in the phase 2 pilot on recommendation to the LJWG by the 
Local Pharmaceutical Committee and needle exchange commissioners. Pharmacy staff were 
trained in the methods of the pilot by the LJWG (see phase 1 report) and provided with a Standard 
Operating Procedure (SOP). Cepheid undertook a joint training session on use of the point of 
care testing machine for representatives from each pharmacy at an evening event. Company 
technicians made regular site visits and were contactable by telephone in case of any queries. 
The care pathway for phase 2 is summarised in Figure 1.  
 
Quantitative data on service users’ testing uptake and onward referral to secondary care was 
captured using a handwritten or electronic form, depending on pharmacy preference (appendix 
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2). A unique ID was generated for each patient and used to track outcome data in terms of 
attendance of secondary care appointments, uptake and completion of treatment.   
 
Feedback questionnaires for pharmacy staff and service users were designed and tested prior 
to implementation (see appendix 2). For service users, the survey was completed over the 
counter at the point of care, and staff feedback was captured at a time convenient for them to 
complete the survey.  
 
Following a request from the LJWG, the Public Health England (PHE) Field Service agreed to 
assist with analysis of the data and report writing. No patient-identifiable information was provided 
to or stored by PHE. Data was analysed in accordance with PHE policies on information 
governance and record keeping. All files will be processed by Field Services South East and 
London (FS SEaL) in accordance with PHE record retention policies.  
 
Quantitative analysis was undertaken using STATA 15. Key themes from the qualitative survey 
were explored to gain further insight into the experiences of patients as well as pharmacy staff. 
 
This pilot evaluated extending access to a standard hepatitis C testing practice that is already in 
use within other areas of the NHS. Care professionals and the service users themselves 
determined the choice of care accessed in line with professional guidance and user preference. 
The pilot was therefore deemed a service evaluation and so a Research Ethics Committee review 
was not required. All staff taking part in the pilot adhered to their respective professional codes 
of ethics in their conduct and actions. 
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Figure 1. Care pathway for hepatitis C testing in pharmacies, LJWG pilot phase 2, 2018-19 
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Results 
Pharmacy engagement 
Six pharmacies took part in the phase 2 pilot between April 2018 and March 2019. The period of 
activity for each pilot site ranged between 15 and 329 days, with a median of 173 days.  
 
The total number of eligible population attending these six pharmacies could not be calculated 
as individuals could register at more than one pharmacy and did not need to provide their unique 
identifiable details such as date of birth or name to obtain NSP pharmacy services. Pilot sites 
reported that 308 patients were offered testing, of which 176 accepted the capillary test. 
Assuming that the data are reliable, this would give a test acceptance rate of 57% (95% 
confidence interval: 51.4% - 62.7%). Among those tested and reporting the reason for attending 
the pharmacy, 83% reported needle exchange and 17% reported both supervised consumption 
and needle exchange as the primary reason for attending the pharmacy.   
 
The number of tests performed by each site during the total pilot period varied between 9 and 
100 (Table 1 and Figure 2). Taking into account the range in activity periods between sites, the 
average number of tests per week ranged between 0.6 tests to 4.2 tests per week.   
 
Further data presented relate to the 176 patients who accepted the offer of testing.  
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Table 1. Activity period and number of tests performed by pharmacies, LJWG pilot phase 2, 2018-
19 
 
Pharmacy First Test Last Test 
Activity 
Period  
(in days) 
Number of 
tests 
conducted (%) 
Average 
tests per 
week 
Portmans Pharmacy  25/04/2018 20/03/2019 329 100 (57%) 2.13 
Junction Pharmacy  10/07/2018 18/12/2018 161 23 (13%) 1 
St Georges Pharmacy  16/05/2018 16/11/2018 184 20 (11%) 0.76 
Market Chemists  19/05/2018 22/11/2018 187 16(9%) 0.6 
Hills Pharmacy  31/05/2018 15/06/2018 15 9 (5%) 4.2 
Mintons Chemist  14/09/2018 24/10/2018 40 8 (5%) 1.4 
Total    176 (100%)  
 
Figure 2.  Activity period and number of tests performed by pharmacies, LJWG pilot phase 2, 2018-
19 
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Demographic factors  
The mean age of those accepting testing was 42 years (range 22 to 61 years) and the majority 
(82%) were male. The age and gender distribution of participants is summarised in the population 
pyramid in Figure 3.  
 
Figure 3. Age-sex pyramid of those accepting HCV testing in pharmacies, LJWG pilot phase 2, 
2018-19 
 
 
Most participants described their ethnicity as White British (n=122; 69%). Other ethnic groups, 
including Asian, Caribbean and mixed backgrounds, constituted almost 19% (n=33), and the 
remaining 12% (n=21) were of other White ethnic background.  
 
Previous testing and treatment  
Over three-quarters (78%; n=135) reported having previously been tested for hepatitis C. Among 
those reporting previous testing, 41% (n= 55) reported being tested within the last year and 56% 
(n=76) reported being tested more than one year ago.  
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As shown in Table 2 below, compared to those tested within the previous year, HCV RNA 
positivity was higher in those who did not report being tested in the previous year, although this 
was not statistically significant (p>0.05). 
 
Table 2. Capillary test result by self-reported previous test date, LJWG pilot phase 2, 2018-19 
 
Self-reported previous test date  Number of patients Capillary test result 
Positive Negative  
Less than one year ago 55  18 (33%) 37 (67%) 
More than one year ago  78  30 (38%) 48 (62%) 
Not known  43  18 (42%) 25 (58%) 
Total 176  66 110 
 
Table 3 shows self-reported previous test result compared with capillary test results. Of note, 
19% of those who reported a previous negative result had a positive result, whereas 63% of 
those who reported a previous positive result continued to be positive. HCV RNA positivity with 
the capillary test was 44% among those who did not know their previous test result.  
 
Table 3. Self-reported previous test result compared to capillary test result, LJWG pilot phase 2, 
2018-19 
 
Self-reported previous test result Number of 
patients 
Capillary test result 
Negative  Positive  
Negative 84  68 (81%) 16 (19%) 
Not known  41  23 (56%) 18 (44%) 
Positive 51  19 (37%) 32 (63%) 
Total 176  110 66 
 
Of the 22 participants who reported having previously received treatment for HCV, 15 reported 
having previously completed HCV anti-viral treatment (3 were HCV RNA capillary test positive) 
and the remaining five reported either partial or no treatment previously (2 were HCV RNA 
capillary test positive).  
 
 
14 
Viral load  
The capillary blood test kit reported viral load for all positive HCV results. Five participants 
(6.58%) had a HCV viral load of 100 IU/ml or less in this cohort. The median viral load was 
468,500 IU/ml (Q1: 62300 IU/ml and Q3: 2,210,000 IU/ml). All participants with a positive test, 
regardless of viral load, were referred to secondary care. 
 
Use of vouchers and peer support 
Among the 66 patients with HCV RNA positive results, contingency management vouchers for 
receiving their result were issued in pharmacies to 64 patients. Peer support was offered to 24 
patients, of which nine who accepted attended secondary care. Of the 36 not offered peer 
support, 12 attended secondary care. 
 
Treatment outcome 
Among 66 patients, 60 patients were referred to secondary care for further investigation and 
treatment, of which 21 attended outpatient appointments. Among six patients who declined 
referral, three had a HCV viral load of <100 IU/ml and the rest had viral load of <300,000 IU/ml.  
 
On genotyping, the majority were genotype 1a (10 patients) or genotype 3 (9 patients). None of 
the participants were HIV or HBV positive.  
 
18 patients started treatment, of which 14 completed treatment and the other four discontinued 
treatment before completion. Among those who completed treatment, four were confirmed to 
have SVR at 12 weeks, eight were pending and two did not attend their appointment.  
 
Among the 21 patients seen in secondary care, four patients were diagnosed as having cirrhosis. 
Of these, two completed treatment, one did not attend their clinic appointment after four weeks 
of treatment and another did not attend for treatment initiation. 
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Figure 4. Care cascade, LJWG pilot phase 2, 2018-19  
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Comparison with Phase 1  
Outcome data was compared between phase 1 and phase 2 pilots for attendance of secondary 
care services and treatment completion. The proportion of patients testing HCV positive in phase 
2 was 37.5%. There was no significant difference between phase 1 and phase 2 with regard to 
attendance at secondary care services (p>0.05) and treatment completion (p>0.05).   
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Table 4. Comparison of LJWG pilot phases 1 and 2, 2018-19 
 
*  Numbers correct at the time of phase 1 and phase 2 report writing; likely to be an underestimate of actual numbers 
completing treatment  
 
Service user feedback  
Service users rated their HCV testing experience on a scale of 1 to 10, with 1 being “very poor” 
and 10 being “excellent”. The mean rating was 9.3 (range 6 to 10). Three-quarters of service 
users reported that they would recommend the pharmacy testing service to a friend.   
 
When asked where they would like to receive HCV treatment if found to be positive on testing, 
the majority (78%) reported they would like to receive it at the pharmacy, followed by 9% of 
service users preferring GP surgery for treatment. The remaining 13% of users were split 
between drug treatment service and hospital as preferred locations for accessing treatment. 
When asked if they were aware that current HCV treatment did not involve interferon injections 
and involved tablets only, 71% reported that they were aware and the rest reported not being 
aware.   
 
Pharmacy feedback  
All six pharmacies provided a feedback response on their experience of taking part in phase 2:   
• Communication from the LJWG (1= very poor, 5= excellent) – mean 4.8 
 
Eligible 
tests 
Proportion positive 
(95% CI) 
Attended 
secondary 
care (%) 
Number 
started 
treatment 
Number 
completed 
treatment  
Phase 1 178 
47.8% 
 HCV antibody 
postive 
(40%-55%) 
23 (27%) 16 2* 
Phase 2 176 
37.5% 
HCV RNA postive 
(30.3-45.1%) 
21 (32%) 18 14* 
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• Willingness of service users to participate (1= not willing to engage, 5= all willing to 
engage) – mean 3.3 
• Ease of testing process (1= very difficult, 5= very easy) – mean 4.5  
• Ease of filling forms (1= very difficult, 5= very easy) – mean 4.8 
• Ease of referral process (1= very difficult, 5= very easy) – mean 4.7  
• Engagement of service users in having a conversation about testing/having the test (1= 
not engaged, 5= very engaged) – mean 3.75  
 
Pharmacy staff reported that they had received generally good feedback from participants, 
appreciating that the service was quick, convenient and easy. The common reasons for declining 
testing reported by pharmacy staff was that the client stated they were busy, or had had the test 
done recently, or wanted to get it done the next time they attended the pharmacy.  One 
pharmacist reported that test uptake was better if the pharmacy had developed a good 
relationship with the service user as part of opiate substitution therapy. Respondents suggested 
ways to improve uptake, including designing posters, leaflets, and working with other 
organisations to raise awareness (e.g. social services and other pharmacies).  
 
Challenges reported by pharmacy staff included difficulties in taking blood, especially in cold 
weather. One pharmacy reported difficulties in working the testing machine.  
 
Pharmacy staff requested confirmation of receipt of referral from secondary care services, as this 
was reported as currently variable. It was suggested that if pharmacy staff were informed of the 
clinic appointment date, they would be able to encourage and remind patients to keep their clinic 
appointment.  
 
Discussion 
Following on from the success of the phase 1 pilot conducted in 2017-18, this report confirms the 
feasibility and value of offering point of care HCV diagnosis to PWIDs attending community 
pharmacies for needle exchange services. Feedback from service users and pharmacy staff for 
HCV testing and referral service has been overwhelmingly positive. Pharmacies providing needle 
18 
exchange services for PWIDs are an important location to “diagnose the undiagnosed” HCV 
cases. 
 
Engagement from pharmacy was suboptimal due to limitations in resources for the pilot, in terms 
of the number of pharmacies signed up to offer testing in phase 2, the activity period when the 
service was offered and the number of tests undertaken among the eligible population. 
Nevertheless, 176 service users were tested, of which 66 were diagnosed with HCV infection. 
Further work is needed to explore how best to improve the engagement of those pharmacies that 
performed less well in offering an HCV testing service.  
 
The reasons for the substantial fall in secondary care attendance following referral are not clear. 
Only a third of patients who were referred went on to attend clinic appointment, suggesting 
barriers in accessing secondary care services. One of the positive findings is that the vast 
majority who attended clinic appointments in secondary care were able to start treatment with 
DAAs and over two-thirds completed treatment. Of note, over three-quarters of users stated 
pharmacies as their preferred location for accessing treatment if it were to be offered.   
 
It is encouraging to note that most service users (78%) reported having been tested for hepatitis 
C previously, with over 30% of all service users being tested within the previous year. An 
important finding is that almost two-fifths of those who reported a previous negative result had a 
positive result, reaffirming the need for regular testing of this high-risk group regardless of 
previous test history. Additionally, self-reported positive previous test appears to be a useful 
marker for HCV infection, with almost two-thirds (63%) of those who reported a previous positive 
result confirmed as having HCV infection by capillary tests. Unsurprisingly, we found that 
positivity was higher in those who did not report being tested in the previous year although this 
was not statistically significant due to small sample size. This also demonstrated re-engagement 
of those previously known to have chronic HCV infection.  
 
Contingency management vouchers were well-utilised in phase 2 and almost all patients 
diagnosed with HCV infection were offered and accepted this incentive. Although peer support 
was offered to some of those testing HCV RNA positive, more work needs to be done to identify 
why the offer and uptake was low. Peer support has been shown to be successful at engaging 
people using drug services in accessing treatment in secondary care (7), so perhaps an adapted 
model is needed in the pharmacy setting. 
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The prevalence of HCV in phase 2 among those tested was 37.5%, which, while lower than the 
phase 1 figure of 48%, needs to be interpreted with caution. The primary reason for this variation 
is that positivity was measured by HCV antibody alone in phase 1 thus identifying those with 
previous exposure to HCV who may not necessarily have chronic HCV infection. Whereas in 
phase 2 HCV RNA was used, providing a more reliable marker of chronic HCV infection. With 
regard to outcome data such as clinic attendance and completion of treatment, there were no 
substantial differences between phase 1 and 2, although the sample sizes were small in both 
phases to detect meaningful differences.  
 
Analysis of the feedback from service users and pharmacy staff has provided further insights to 
inform wider implementation of this programme. It is important that relevant written materials 
including SOP and referral letters are developed and shared with pharmacies providing this 
service, and adequate training is provided to pharmacy staff on HCV, test counselling, use of 
testing equipment and the referral process. Secondary care providers should consider how best 
to acknowledge referral of new patients by community pharmacists if this is not routinely done.  
Almost 30% of patients were not aware that newer tablet treatments are available for HCV, 
suggesting scope for further development of resources to raise awareness, such as leaflets and 
posters, and holding engagement events.    
 
There are several limitations to this study. First, while pharmacy staff received training on test 
counselling and use of the point of care machine, standardised practice between pilot sites 
cannot be guaranteed, and there may be some systematic differences in how the pilot was 
conducted at pharmacy level. Furthermore, differing levels of engagement of pharmacy staff 
could have had an impact on the number of people invited to take part in the pilot. Second, due 
to current service configuration and operational reasons, it was not possible to measure or 
estimate the overall population of PWIDs attending the six pharmacies who would have been 
eligible for testing in the phase 2 pilot. Third, data on previous testing and treatment was provided 
by service users and could not be verified for reliability. The use of free text and lack of data 
format requirements also led to poor quality information for certain variables (e.g. previous test 
date) and necessitated a degree of estimation to collapse into categories. Fourth, we were unable 
to adequately capture the reasons why two-thirds of those testing positive for HCV did not attend 
secondary care service for further assessment and treatment.   
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Recommendations 
1. HCV testing and treatment is necessary for PWIDs actively injecting. 37.5% of those 
tested had chronic HCV infection, which is higher than that seen in the prison population. This 
confirms the importance of testing and treating this vulnerable population. 
 
2. HCV testing should be rolled out in selected pharmacies across the country. The recent 
Community Pharmacy Contractual Framework for 2019/20 to 2023/24 provides an exciting 
opportunity to expand hepatitis C testing for people accessing needle exchanges in community 
pharmacies (8). With £4 million announced to fund hepatitis C testing in this setting, this report, 
alongside the phase 1 report (6), has provided key insights to delivering testing in pharmacies. 
To avoid duplicating efforts and to ensure people who are at risk of infection or re-infection 
through injecting drug use are targeted effectively, the SOPs developed for this and the previous 
pilot have the potential to be utilised in developing a testing programme.   
 
3. A campaign targeting actively injecting PWIDs is needed to increase awareness that 
treatment for HCV is now all oral tablets.  This may increase the uptake of both testing and 
treatment in this at-risk population.  
 
4. The Government should overcome legislative barriers to support the roll-out of hepatitis 
C treatment in pharmacies. When asked where they would prefer to be treated for hepatitis C, 
the majority of people already accessing a hepatitis C test at a community pharmacy in both 
phase 1 (84%) and phase 2 (78%) of the pilot said they would like treatment in the same setting. 
This, together with the significant drop-out at the secondary care attendance level, requires a 
more patient centred approach to HCV treatment delivery. The Department of Health and Social 
Care needs to overcome the legislative barrier preventing hepatitis C treatment from being 
dispensed in pharmacies so that those most at risk can more readily access medication. 
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Dr Matthew Foxton, Consultant Hepatologist Chelsea and Westminster Hospital 
John Gibbons, Groundswell  
Dr Indrajit Ghosh, Specialty Doctor, Mortimer Market Centre, CNWL NHS FT 
Sam Gokal, Mintons Pharmacy 
Rachel Halford, Chief Executive, The Hepatitis C Trust  
Lorna Harrison, Clinical Nurse Specialist, Hepatology, Imperial College  
Sarah Hart, Senior Commissioner for Substance Misuse and Sexual Health, Public Health, 
Haringey   
Sarah Hodgson, Hepatology Specialty Nurse, Kings College London  
Mike Kelleher, Consultant Addictions Psychiatrist, Lorraine Hewitt House Lambeth 
Chris Laker, Peer Support Lead, South East London, The Hepatitis C Trust  
Michael Levitan, Chief Executive, Middlesex Pharmaceutical Group  
Urte Macikene, Principle Consulting 
Dr Sema Mandal, National Infection Service, PHE 
Laura Manders, Portmans Pharmacy  
Raj Matharu, Chief Executive, Lambeth, Southwark & Lewisham Local Pharmaceutical 
Committee  
Serena McCabe, Clinical Services Manager (Substance Misuse), Barnet, Enfield and Haringey 
Mental Health NHS Trust  
Martin McCusker, Lambeth Service User Council  
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Fred McGruer, Nurse Manager, Turning Point  
Miranda Mindlin, Consultant in Communicable Disease Control, PHE London 
Shiraz Mohamed, Market Chemists 
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Michael O'Sullivan, Junction Pharmacy 
Akeem Ogunyemi, Commissioner, Sexual Health, Haringey Council  
Dr Karthik Paranthaman, Consultant Epidemiologist, Field Service, PHE  
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Atul Patel, St Georges Pharmacy Southwark  
Bhaveen Patel, Junction Pharmacy Brixton  
Hemang Patel, Turning Point 
Jasumati Patel, Portmans Pharmacy 
Jayesh Patel, CEO Lambeth Southwark and Lewisham LPC 
Tushar Patel, Mintons 
Vikash Patel, Mintons 
Sharon Pedliham, Kensington and Chelsea Borough Manager  
Michele Roberts, Public Health, Hammersmith and Fulham  
Sarah Robinson, Head of Programmes, Health Protection, Public Health Southwark  
Prof William Rosenberg, University College London  
Ahmad Sadiqzai, Market Chemists 
Amit Shah, Superintendent Pharmacist, AR Chemist  
Rekha Shah, Chief Executive, Kensington Chelsea & Westminster LPC 
Sital Shah, Senior Clinical Pharmacist, Liver Services, Kings College Hospital  
Terry Shields, Needle Exchange Coordinator, South London and Maudsley NHS Foundation 
Trust 
Rhiannon Sheppard, Clinical Nurse Specialist, Hepatology, Chelsea and Westminster Hospital  
Dr Caroline Shulman, General Practitioner in Homeless and Inclusion Health, Kings Health 
Partnership  
Ruth Simmons, PHD Epidemiologist, PHE  
Lizzie Smith, HCV Programme Manager, STHepNet ODN  
Stuart Smith, Director of Community Services, The Hepatitis C Trust 
Mark Stone, Devon LPC Project Pharmacist 
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Shailesh Thakrar, My Pharmacy 
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General Hospital and Hon Senior Lecturer, School of Medical Sciences, University of Manchester 
Dr Marie Noelle Vieu, Public Health Consultant, Health Protection, Lambeth Council 
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 Appendix 1- HCV testing paperwork (Data collection form) 
       Hepatitis C Screening Service 
  London Pharmacies 
Client Questionnaire 
1. Did you attend pharmacy for: 
 
Needle X    o   Supervised Consumption & Needle X   o Other o 
 
2. Do you attend a drug and alcohol service. Yes o No o 
2. Were you aware of the Hepatitis C testing service before you came today? 
 
Yes o No o If yes where did you hear about the testing service? 
3. If you require treatment where would you ideally receive this? 
 
Hospital o GP o Pharmacy o Drug Treatment Service o 
 
Other o (Please Specify): 
4. How would you rate the test experience you received today? 
 
Very Poor 1 2 3 4 5 6 7 8 9 10 Excellent 
5. Would you recommend this test to a friend? 
 
Yes o No o 
6. If No, why not? 
7. Are you aware current treatment does not involve interferon injections and is 
tablets only? 
 
Yes o No o 
 
Pharmacy Stamp GP Name and address 
 
 
 
o Not registered with a GP 
Date of test:  
Client Name:  
Date of Birth:  
Gender Male o Female o 
Ethnic Origin: White British  o White Irish o White Other o 
Black British  o Black African o Black Caribbean o 
Black Other  o Asian British o South Asian o 
East Asian  o Asian Other o Mixed o 
Other:     Rather not Say o 
Contact Address: 
 
 
Post Code: 
 
Telephone No:  
Alternative No:  Contact 
Relationship: 
 
If we are unable to contact you do you give consent to speak to 
your alternative contact? 
Yes o No o 
Testing History 
Have you been tested for 
Hepatitis C previously? Yes o No o Don’t know o 
Approximate Date of last test:  
Location: GP o Drug/Alcohol Service o Sexual Health Service o 
Other: 
Results: Positive o Negative o Not known o 
Have you been treated for 
Hepatitis C previously? Yes o No o Don’t know o 
 
 Test Results 
Hepatitis C RNA o Positive o Negative 
Unique identifier   IU/ML   
If test declined why? Already tested o already HCV positive o Not interested o 
Addition information - 
Results Appointment Done 
Information about Hepatitis C, on treatment available and give client a 
copy of 'Hep C Info' or 'Hep C Care booklet 
 
Advice on how to prevent passing Hepatitis C to others  
Client referred on to appropriate local service for further assessment and 
treatment 
 
Contingency Management Voucher accepted?  
If referred on please state where they 
have been referred to: 
 
Peer support offered: Accepted o Declined  o 
Peer assigned: Yes o No o 
Negative Results Checklist Done  
Recommend re-test if at risk recently (3 month window period)  
Advise on prevention in future and give negative test information  
If they are at risk of Hepatitis B or HIV recommend testing and hepatitis 
B vaccination 
 
If they remain at risk from Hepatitis B, recommend vaccination  
Declined Tests Checklist (fill in 
daily) 
No interest Already tested Other 
 
This document has been produced for the LJWG on Substance Use and Hepatitis C 
for use by pharmacies participating in the HCV testing pilots Phase 2. 
This document has been adapted from a document provided by Graham Parsons from 
Turning Point and the Devon Local Pharmaceutical Committee. The LJWG would like to 
thank Graham and the Devon LPC for permission to adapt this paperwork for use within 
this pilot. 
 
Can you remember 
where and when? 
  
Did you complete treatment 
and informed you were cured? 
 
Pre-Test Check List Done 
Explained what GeneXpert process will entail  
Explained how and when results will be given and arrangements for follow- 
up for a positive RNA test, including referral 
 
Explained possible 3 month window period for re-testing if recently at risk  
Offered contingency management voucher of £5  
Explanation of the implications of a positive result Done 
They may have difficulty securing Life / Health Insurance as is common 
with many chronic (long term) illnesses 
 
Hepatitis C can lead to severe liver damage and an increased risk of cancer. 
However there is effective treatment available. 
 
They have received a copy of the hepatitis B and C information.  
Consent 
• I have had the GeneXpert explained to me and I consent to the test being taken 
and anonymous information being used by the LJWG, the local health service and 
Chelsea and Westminster Hospital. 
• I consent to the specialist service at the hospital being given details of any positive 
RNA test results. 
• If the test result is positive I am happy for my contact details to be shared with The 
Hepatitis C Trust who can provide support to access treatment. 
If you would prefer not to do this please tick this box. o 
• I am happy for the test results to be shared with my GP if blood tests show that I 
have been diagnosed positive for a blood born virus – This is to ensure that you 
can receive the best care possible if your test result is positive and the GP is aware 
of current medications. 
• If you do not collect your GeneXpert results we will forward them to your GP. If 
you would prefer we don’t do this please tick this box o 
 
Client Signature: Date: 
 
 Appendix 2- Hospital referral form  
 
